Source: International Congress 2019 – Asthma and the world
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Scott (Bollington, United Kingdom), M. Small (Bollington, United Kingdom). Comorbidities, hypersensitivity and biomarkers in a real-world US nasal polyps population. 5066

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 The clinical relationship of nasal polyposis to asthma and other pathologies in the French population Source: Eur Respir J 2003; 22: Suppl. 45, 114s Year: 2003 Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Nasal mucosa biopsy in severe astma patiens as a tool for the prediction of the inflammatory changes in lower airways Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring Year: 2010 The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Effect of mepolizumab on chronic rhinosinusitis symptoms and nasal hypersensitivity in patients with or without nasal polyps Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities Year: 2020 Influence of obesity and nasal polyps on severe asthma Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement Year: 2013 Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Patient characteristics and treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Canada Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 IL-19 as putative biomarker for chronic rhinosinusitis with nasal polyps Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010 Biomarkers of airways inflammation in patients with severe asthma in a real clinical practice Source: International Congress 2019 – Long-term evaluation and control of airway diseases Year: 2019 Are asymptomatic airway hyperresponsiveness and allergy risk factors for asthma? A longitudinal study Source: Eur Respir J 2008; 32: 70-76 Year: 2008 Are asymptomatic airway hyperresponsiveness and allergy risk factors for asthma? A longitudinal study Source: Eur Respir J 2009; 33: 218-219 Year: 2009 Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Real-world evidence of reported symptoms and quality of life burden associated with chronic rhinosinusitis with nasal polyposis and comorbid asthma status Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021